ResMed (RMD) Reports In-Line Q3 EPS
ResMed (NYSE: RMD) reported Q3 EPS of $0.65, in-line with the analyst estimate of $0.65. Revenue for the quarter came in at $422.5 million versus the consensus estimate of $425.76 million.
For earnings history and earnings-related data on ResMed (RMD) click here.